Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[International prognostic index in diffuse B large cell lymphosarcoma].

A U Magomedova, A I Vorob'ev

    Terapevticheskii Arkhiv
    |April 30, 2008
    PubMed
    Summary

    The International Prognostic Index (IPI) is not a reliable predictor for diffuse B-large cell lymphosarcoma (BLCLS) treatment outcomes. Primary lesion site is a more significant prognostic factor than IPI grouping for BLCLS patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.

    Bulletin of experimental biology and medicine·2021
    Same author

    Pitfalls in mononucleotide microsatellite repeats instability assessing (MSI) in the patients with B-cell lymphomas.

    Klinicheskaia laboratornaia diagnostika·2021
    Same author

    Analysis of Bone Tissue Condition in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement.

    Bulletin of experimental biology and medicine·2020
    Same author

    [CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].

    Terapevticheskii arkhiv·2020
    Same author

    [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].

    Terapevticheskii arkhiv·2020
    Same author

    [Follicular lymphoma: first - line selection criteria of treatment].

    Terapevticheskii arkhiv·2020

    Area of Science:

    • Oncology
    • Hematology
    • Clinical Research

    Background:

    • Diffuse B-large cell lymphosarcoma (BLCLS) is an aggressive non-Hodgkin lymphoma.
    • Accurate prognostic factors are crucial for effective treatment strategies in BLCLS.

    Purpose of the Study:

    • To evaluate the efficacy of the International Prognostic Index (IPI) in predicting outcomes for BLCLS patients.
    • To identify significant prognostic factors beyond the IPI for BLCLS.

    Main Methods:

    • A cohort of 121 BLCLS patients were analyzed.
    • Patients received various chemotherapy regimens including CHOP-21, R-CHOP-21, and NHL-BFM-90.
    • Surgical interventions (splenectomy) and radiotherapy were employed for specific patient groups.

    Main Results:

    • The IPI showed limited validity in predicting 5-year event-free survival across different risk groups.
    • Patients with solitary peripheral lymph node lesions had a 97% survival rate, while tonsillar lesions had a 50% survival rate.
    • Patients with primary splenic lesions achieved 100% 5-year event-free survival after splenectomy, chemotherapy, and radiotherapy.

    Conclusions:

    • The IPI is not a definitive tool for determining therapy choices in BLCLS.
    • The site of the primary lesion is a more critical prognostic indicator than IPI-based risk stratification for BLCLS.

    Related Experiment Videos